drugset
drugset / Trial / NCT05039710

A Study of JNJ-75220795 in Japanese Participants

NCT05039710 ↗

Phase 1 Terminated 9 enrolled Janssen Pharmaceutical K.K.
RandomizedSequentialDouble-blindTreatment

Summary

The purpose of this study is to assess the safety and tolerability of single subcutaneous (SC) dose of JNJ-75220795 in Japanese participants.

Timeline

Start
2021-11-08
Primary completion
2023-02-17
Completion
2023-02-17

Outcome

Outcome not reported

Stopped (Business): “Business Judgement”

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-75220795 Unknown — Subcutaneous

Indications

fatty liver disease